Research Papers:

PTEN expression is a prognostic marker for patients with non-small cell lung cancer: a systematic review and meta-analysis of the literature

Jian Xiao, Cheng-Ping Hu, Bi-Xiu He, Xi Chen, Xiao-Xiao Lu, Ming-Xuan Xie, Wei Li, Shu-Ya He, Shao-Jin You and Qiong Chen _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:57832-57840. https://doi.org/10.18632/oncotarget.11068

Metrics: PDF 6821 views  |   HTML 3121 views  |   ?  


Jian Xiao1, Cheng-Ping Hu2, Bi-Xiu He1, Xi Chen2, Xiao-Xiao Lu1, Ming-Xuan Xie1, Wei Li1, Shu-Ya He3, Shao-Jin You4, Qiong Chen1

1Department of Geriatrics, Respiratory Medicine, Xiangya Hospital of Central South University, Changsha 410008, China

2Department of Respiratory Medicine, Xiangya Hospital of Central South University, Changsha 410008, China

3Department of Biochemistry and Biology, University of South China, Hengyang 421001, China

4Laboratory of Cancer Experimental Therapy, Atlanta Research and Educational Foundation (151F), Atlanta VA Medical Center, Decatur, GA 30033, USA

Correspondence to:

Qiong Chen, email: [email protected]

Keywords: non-small cell lung cancer, NSCLC, PTEN, disease free survival, DFS

Received: June 07, 2016     Accepted: July 20, 2016     Published: August 05, 2016


Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a known tumor suppressor in non-small cell lung cancer (NSCLC). By performing a systematic review and meta-analysis of the literature, we determined the prognostic value of decreased PTEN expression in patients with NSCLC. We comprehensively and systematically searched through multiple online databases up to May 22, 2016 for NSCLC studies reporting on PTEN expression and patient survival outcome. Several criteria, including the Newcastle-Ottawa Quality Assessment Scale (NOS), were used to discriminate between studies. In total, 23 eligible studies with a total of 2,505 NSCLC patients were included in our meta-analysis. Our results demonstrated that decreased expression of PTEN correlated with poor overall survival in NSCLC patients and was indicative of a poor prognosis for disease-free survival and progression-free survival in patients with NSCLC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11068